Sanofi Eyes Low Single-Digit EPS Growth For 2024 After Opella Stake Transfer, Forecasts Strong Rebound In 2025
Portfolio Pulse from Benzinga Newsdesk
Sanofi has adjusted its 2024 EPS growth guidance to low single-digit growth after transferring its Opella stake. The company anticipates a strong rebound in 2025.
October 21, 2024 | 6:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi has revised its 2024 EPS growth guidance to low single-digit growth following the transfer of its Opella stake. The company expects a strong rebound in 2025.
Sanofi's adjustment of its 2024 EPS guidance to low single-digit growth reflects a strategic shift after the Opella stake transfer. The anticipation of a strong rebound in 2025 suggests confidence in future performance, likely positively impacting investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100